Dr Yu Hu speaks to ecancer at the ASH 2019 meeting in Orlando about a study looking at the use of bispecific CAR T-cell therapy as treatment for hard to treat multiple myeloma.
Dr Hu explains that usually CAR T-cell therapies target one antigen but this new therapy can target two: Bcma and CD38.
He reports that the study demonstrated improved efficacy with a high overall response rate and also was effective in eliminating for extramedullary tumours.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.
Watch the press conference here.
Read more about the study here.